[Subgroup Analysis of the Non-interventional REASON Study: PFS and OS According to Age, Smoking History, Gender, and Histology in NSCLC Patients Treated with Gefitinib or Chemotherapy].
OBJECTIVE
Assessment of several clinical factors on progression-free (PFS) and overall survival (OS) in NSCLC patients (pts.) (stage IV) with mutated epidermal growth factor receptor (EGFRm+) treated with gefitinib (gef) or with chemotherapy (CT) under real-world conditions.


METHODS
285 EGFRm+ pts. of the non-interventional REASON study treated with gef (n = 206) or CT (n = 79) as first-line therapy or with gef (n = 213) or CT (n = 61) in any line throughout the course of therapy were analyzed according to age, gender, smoking history and histology.


RESULTS
Compared with CT, patients treated with gef showed prolongation of PFS and OS in all subgroups. PFS was significantly increased in women and non-smokers. OS was significantly increased in women, non-smokers, (ex)-smokers, patients with adenocarcinoma and elderly patients when treated with gef compared to CT. Female gender turned out to be an independent positive predictive factor for OS in patients treated with gef (HRmale: 1.74, p = 0.0009).


CONCLUSIONS
A clinical benefit of gef was shown for all analyzed clinical subgroups of EGFRm+ pts. This was confirmed for the female gender in a multivariate analysis.
Krankenhaus Martha-Maria Halle-Doelau, Klinik für Innere Medizin II, Halle.
W
W
Schuette
Innere Klinik (Tumorforschung), Ruhrlandklinik, Westdeutsches Tumorzentrum (WTZ), Essen, Universitätsklinikum Essen, Universität Duisburg-Essen.
W E E
WE
Eberhardt
Klinik für Innere Medizin I, Universitätsklinikum Freiburg.
C
C
Waller
Pathologisches Institut, Universitätsklinik Heidelberg.
P
P
Schirmacher
Pathologisches Institut, Humboldt Universität Berlin.
M
M
Dietel
iOMEDICO AG, Freiburg;
U
U
Zirrgiebel
Medical Affairs, AstraZeneca, Wedel;
S
S
Radke
Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg.
M
M
Thomas
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D000077156:Gefitinib; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011799:Quinazolines / Q000008:administration & dosage*; D012307:Risk Factors; D017678:Sex Distribution; D012907:Smoking / Q000453:epidemiology*; D016019:Survival Analysis; D016896:Treatment Outcome
D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib